GenEros key facts
- Developer of therapeutics intended for the treatment of autoimmune diseases and cancer.
- Notable investors include Heda Ventures, Cherami Investment Group, BVCF.
- Status: Privately Held (backing).
Who backs GenEros
3- ·Watch GenEros: the Monday email on marks, rounds and moves
GenEros funding rounds
No funding rounds for GenEros are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
GenEros investors
3 investors are on record for GenEros, including Heda Ventures, Cherami Investment Group and BVCF.
About GenEros
Developer of therapeutics intended for the treatment of autoimmune diseases and cancer. The company offers molecular profiling for precision treatment, and leverages translational research collaborations, enabling immunology and oncology markets to access mechanism-driven, pathway-specific therapeutic solutions.
- Sector
- Healthcare
- HQ
- Hangzhou, China
- Founded
- 2018
- Website
- generosbio.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.
GenEros doesn't have a valuation on record yet — one is published once a priced round, a reported valuation, fund marks, or secondary prints surface in our sources. The rest of the record below builds toward it.